| 1 | Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. 2019;10:5510 doi: 10.18632/oncotarget.27140 |
| 2 | Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study. 2020;28:741 doi: 10.1097/PAI.0000000000000841 |
| 3 | Radiation-induced DNA damage response and resistance in colorectal cancer stem-like cells. 2019;95:667 doi: 10.1080/09553002.2019.1580401 |
| 4 | ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy. 2020;27:251 doi: 10.3233/CBM-190994 |
| 5 | Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway. 2020;204:112658 doi: 10.1016/j.ejmech.2020.112658 |
| 6 | Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1–XPF. 2019;62:7684 doi: 10.1021/acs.jmedchem.9b00326 |
Journal of Cancer Metastasis and Treatment
